Palatin Technologies Inc New (PTN) News

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide...

Palatin Appeals NYSE American Notice of Delisting

Palatin Appeals NYSE American Notice of Delisting PR Newswire CRANBURY, N.J., April 14, 2025 Company working...

Form 8-K - Current report

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal PR...

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National...

Form RW WD - Withdrawal of Registration Withdrawal Request

Form RW - Registration Withdrawal Request

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint...

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1...

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update PR...